Apogee Therapeutics, Inc. (APGE)
135.07
-0.01
(-0.01%)
USD |
NASDAQ |
Sep 02, 16:00
Apogee Therapeutics Research and Development Expense (TTM) : 240.59M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 240.59M |
| March 31, 2026 | 229.00M |
| December 31, 2025 | 214.50M |
| September 30, 2025 | 216.36M |
| June 30, 2025 | 207.90M |
| March 31, 2025 | 185.47M |
| December 31, 2024 | 167.86M |
| September 30, 2024 | 136.59M |
| Date | Value |
|---|---|
| June 30, 2024 | 107.94M |
| March 31, 2024 | 88.68M |
| December 31, 2023 | 68.42M |
| September 30, 2023 | 51.68M |
| June 30, 2023 | 44.49M |
| March 31, 2023 | 32.00M |
| December 31, 2022 | 27.79M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Cogent Biosciences, Inc. | 285.88M |
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Intellia Therapeutics, Inc. | 337.63M |
| Revolution Medicines, Inc. | 1.287B |
| Erasca, Inc. | 108.88M |